Further experiments identified that Metrnl antagonized obesity‐induced insulin resistance by improving adipose function, including adipocyte differentiation, metabolism activation, and inhibiting adipose inflammation through the PPARγ pathway.13 A clinical study also showed that serum Metrnl level was decreased and negatively correlated with glucose level and insulin resistance in patients with diabetes.14 Chung et al15 found that circulating Metrnl level was inversely related to various cardiometabolic risk factors including body composition, components of metabolic syndrome. Here, PPARG is linked to metabolic syndrome.